SecBot SecBot
PRESS-RELEASE ·Filed Apr 15, 2026

RVMD

Revolution Medicines, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The large capital raise signals extended runway for clinical development but introduces substantial near-term dilution. The 40% conversion premium suggests management confidence in future stock appreciation, but the size of the offering, combined with recent insider selling, may pressure shares short-term. Traders should monitor use of proceeds and clinical trial milestones as forward catalysts.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$152.54
T+0 close · Apr 15, 2026 · via day close
Latest settled
+22.51%
T+60 · $186.88
Vs SPY
+14.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $152.54entry
  2. T+1 · 7mo ago −2.14%α −2.40% · $149.27
  3. T+5 · 7mo ago −7.24%α −8.88% · $141.50
  4. T+20 · 6mo ago −4.47%α −10.51% · $145.72
  5. T+60 · 4mo ago +22.51%α +14.38% · $186.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common stock at $142.00 per share, raising $1.5B gross, and $500M in 0.50% convertible senior notes due 2033, increasing both offerings from previously announced sizes. Net proceeds are expected to total approximately $1.92B ($1.435B from stock, $486.8M from notes), to be used for R&D, commercialization, and general corporate purposes.

Key Financial Metrics

Deal Value
$2.0B

Key Facts

  • Priced concurrent offerings: $1.5B common stock offering and $500M convertible note offering
  • Common stock priced at $142.00 per share; 10,563,381 shares issued
  • Convertible notes have 0.50% coupon, mature May 1, 2033, with $500M principal
  • Offering sizes increased from initial $750M (stock) and $250M (notes)
  • Underwriters granted 30-day option to purchase up to 1,584,506 additional shares
  • Initial conversion price for notes: ~$198.80 per share (40% premium to stock offering price)
  • Net proceeds estimated at $1.435B (stock) and $486.8M (notes), totaling ~$1.92B
  • Proceeds to fund R&D, commercialization, and general corporate expenses
  • Recent insider selling: $3.1M across 8 transactions in past 30 days

Financial Impact

Approximately $1.92B in net proceeds, but significant dilution from equity raise and potential conversion of notes

dilutioncashdebtequity

Risk Factors

  • Significant equity dilution from $1.5B common stock offering
  • Potential for future share overhang if convertible notes are equity-settled
  • Market may interpret large capital raise as lack of confidence in near-term commercial viability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274107

US Market Status

Market Closed · Opens in 8h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026